Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

Sandra Ortiz‐Cuaran, Matthias Scheffler, Dennis Plenker, +33

Clinical Cancer Research

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Johannes M. Heuckmann, Hyatt Balke‐Want, Florian Malchers, +9

Clinical Cancer Research

Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer

Sampurna Chatterjee, Lukas C. Heukamp, Maike Siobal, +15

Journal of Clinical Investigation

Vegf ProductionOncologyAngiogenesisMedicineTumor Growth +13

Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice

Lukas C. Heukamp, Theresa Thor, Alexander Schramm, +22

Science Translational Medicine

<scp>NOTCH</scp>, <scp>ASCL1</scp>, p53 and <scp>RB</scp> alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas

Lydia Meder, Katharina König, Luka Ozretić, +14

International Journal of Cancer

Cancer ResearchPrimary SclcRare Secondary SclcAlternative PathwayTumor Microenvironment +13

Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer

Lydia Meder, Philipp Schuldt, Martin Thelen, +19

Cancer Research

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

Daniel Thomalla, Laura Beckmann, Christina Grimm, +34

Blood

EngineeringMixed-phenotype Acute LeukemiaGeneticsImmunologyPathology +21

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

Katharina König, Martin Peifer, Jana Fassunke, +31

Journal of Thoracic Oncology

BioinformaticsSequence AssemblyOncologyMedicineNext-generation Sequencing +10

MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I

Johannes Brägelmann, Carina Lorenz, Sven Borchmann, +36

Nature Communications

Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer

Soeren Latteyer, Vera Tiedje, Katharina König, +6

Endocrine

Health SciencesTumor HeterogeneityMedicineThyroid DiseaseNf1 Mutations +8